AGMB (AgomAb Therapeutics NV) Total Assets: $179.98 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Total Assets?

AgomAb Therapeutics NV AGMB +0.85% 14 Total Assets is $179.98 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's Total Assets for the quarter that ended in Dec. 2025 was $179.98 Mil.

During the past 12 months, AgomAb Therapeutics NV's average Total Assets Growth Rate was 19.20% per year. During the past 3 years, the average Total Assets Growth Rate was 7.30% per year.

During the past 5 years, AgomAb Therapeutics NV's highest 3-Year average Total Assets Growth Rate was 7.30%. The lowest was 2.10%. And the median was 4.70%.

Total Assets is connected with ROA %. AgomAb Therapeutics NV's annualized ROA % for the quarter that ended in Dec. 2025 was -43.54%. Total Assets is also linked to Revenue through Asset Turnover. AgomAb Therapeutics NV's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

AgomAb Therapeutics NV  (NAS:AGMB) Total Assets Explanation

Total Assets is connected with ROA %.

AgomAb Therapeutics NV's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-81.504/( (194.403+179.984)/ 2 )
=-81.504/187.1935
=-43.54 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

AgomAb Therapeutics NV's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (194.403+179.984)/ 2 )
=0/187.1935
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

AgomAb Therapeutics NV Total Assets Related Terms

AgomAb Therapeutics NV Total Assets Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Total Assets Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
94.91 106.99 186.76 216.08 179.98

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Total Assets Get a 7-Day Free Trial 106.99 186.76 216.08 194.40 179.98
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

AgomAb Therapeutics NV's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=153.281+26.703
=179.98

AgomAb Therapeutics NV's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=153.281+26.703
=179.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $179.98 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Total Assets of $179.98 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Total Assets too high?
AgomAb Therapeutics NV's current Total Assets is $179.98 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Total Assets compare to DNA and ACRS?
AgomAb Therapeutics NV's Total Assets of $179.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Total Assets is $179.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Total Assets of $179.98 Mil. The current Total Assets is $179.98 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Total Assets is $179.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price